Showing 311-320 of 1698 results for "".
- Muscular Dystrophy Association and Magic Wheelchair Launch 2022 Halloween Costume Competition to Raise Neuromuscular Disease Awarenesshttps://practicalneurology.com/news/muscular-dystrophy-association-and-magic-wheelchair-launch-2022-halloween-costume-competition-to-raise-neuromuscular-disease-awareness/2469729/The Muscular Dystrophy Association (MDA) and Magic Wheelchair have launched a Instagram competition to win a Magic Wheelchair Halloween costume in 2022. To enter, participants with neuromuscular diseases need to follow@MDAorg and @MagicWheelchair on Instagram and comment with a purple heart on al
- Sudden Unexpected Death in Epilepsy More Prevalent in Black and Multiracial Childrenhttps://practicalneurology.com/news/sudden-unexpected-death-in-epilepsy-more-prevalent-in-black-and-multiracial-children/2469452/Findings from a large national registry presented virtually at the American Epilepsy Society AES2020 revealed that sudden unexpected death in epilepsy (SUDEP) is more common in infants and children than previously reported. The population-based study—the first of its kind in the US—fo
- Vascular Health and Treating Migrainehttps://practicalneurology.com/news/vascular-health-and-treating-migraine/2469440/As new migraine treatments have become available that do not have cardiovascular contraindications, many questions have arisen regarding whether a new therapy—lasmiditan—is truly safe for those with cardiovascular risk. These important considerations for the 12% of peo
- Muscular Dystrophy Association Launches Data Reporting and Visualization Platform for Neuromuscular Diseasehttps://practicalneurology.com/news/muscular-dystrophy-association-launches-data-reporting-and-visualization-platform-for-neuromuscular-disease/2469411/The Muscular Dystrophy Association (MDA) has announced the availability of its new data sharing platform, the neuromuscular observational research (MOVR) visualization and reporting platform (VRP). MOVR-VRP represents a milestone in advancing neuromuscular disease research and improving patient c
- FDA Approves Expanded use of Pitolisant for Treatment of Cataplexy in Adults With Narcolepsyhttps://practicalneurology.com/news/fda-approves-expanded-use-of-pitolisant-for-treatment-of-cataplexy-in-adults-with-narcolepsy/2469405/The Food and Drug Administration (FDA) approved pitolisant (Wakix; Harmony Biosciences Plymouth Meeting, PA)—treatment of cataplexy in adults with narcolepsy. Pitolisant is the first and only treatment not categorized as a controlled substance that is approved by the FDA for treating sympto
- High-Dose Biotin Did Not Improve Disability for Individuals With Active Secondary Progressive MS in Phase 3 Trialhttps://practicalneurology.com/news/high-dose-biotin-did-not-improve-disability-for-individuals-with-active-secondary-progressive-ms-in-phase-3-trial/2469189/The second pivotal phase 3 trial (SPI2) (NCT02936037) of investigational high-dose biotin (MD1003, MedDay Pharmaceuticals, Boston, MA) did not improve disability for individuals with active secondary p
- FDA Authorizes First Test to Aid in Newborn Screening for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-authorizes-first-test-to-aid-in-newborn-screening-for-duchenne-muscular-dystrophy/2469111/The Food and Drug Administration (FDA) has authorized marketing of the 1st test to aid in newborn screening for Duchenne Muscular Dystrophy (DMD). The test (GSP Neonatal Creatine Kinase—MM; PerkinElmer, Inc., Waltham, MA) works by measuring the concentration of the CK-MM protein, which is p
- Combined Lifestyle Interventions May Offset Alzheimer’s Disease Riskshttps://practicalneurology.com/news/combined-lifestyle-interventions-may-offset-alzheimers-disease-risks/2468957/Research findings reported at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 suggest that healthy lifestyle choices—including diet, exercise, and cognitive stimulation—may decrease risk of cognitive decline and dementia.
- Clinical Trial of Rimegepant for Trigeminal Neuralgia Enrolls First Participanthttps://practicalneurology.com/news/clinical-trial-of-rimegepant-for-trigeminal-neuralgia-enrolls-first-participant/2468946/The first patient has been enrolled in a double-blind placebo-controlled clinical trial (NCT03941834) to assess rimegepant (Biohaven Pharmaceuticals, New Haven, CT)—a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist—for treatment of trigeminal neuralgia refrac
- OnabotulinumtoxinA Approved for Treatment of Children with Upper Limb Spasticityhttps://practicalneurology.com/news/onabotulinumtoxina-approved-for-treatment-of-children-with-upper-limb-spasticity/2468936/The Food and Drug Administration (FDA) has approved a new indication for onabotulinumtoxinA (Botox; Allergan, Madison, NJ)—treatment of upper limb spasticity in children, age 2 to 17 years. The decision came after a 6-month priority review, which istypically granted to therapies with potent